India, Aug. 11 -- Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended June 30, 2026, reflecting a wider net loss and provided corporate updates.
Sagimet focuses on developing fatty acid synthase (FASN) inhibitors for diseases associated with abnormal production of the fatty acid palmitate.
The company has made a strategic decision to focus on dermatology, with acne as its lead development area.
Company's Pipeline Details
The company's lead candidate is Denifanstat, an oral, once-daily, selective FASN inhibitor being developed for moderate-to-severe acne and was previously evaluated in MASH.
The company is also developing TVB-3567, its second oral, selective FASN ...